Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study.
J Immunother CancerSep 8, 2026 (epub)
Clinical ResearchOncology (Medical)
Jin Xia, Xiangrui Meng, Guozhong Jiang et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter phase II study evaluated the efficacy and safety of camrelizumab plus nimotuzumab in 46 patients with advanced esophageal squamous cell carcinoma (ESCC) after first-line therapy failure. The confirmed objective response rate (ORR) was 32.6%, with a disease control rate of 82.6%. Median progression-free survival was 9.13 months, and median overall survival was 12.62 months.
Key findings
- Confirmed ORR was 32.6% (15/46; 95% CI 19.5 to 48.0).
- Median progression-free survival was 9.13 months (95% CI 5.95 to 9.76).
- Median overall survival was 12.62 months (95% CI 9.40 to 15.01).
- Patients with EGFR amplification had a higher ORR of 47.1%.
Why it matters
The study highlights a potential second-line treatment option for advanced ESCC, particularly for patients previously treated with immune checkpoint inhibitors, addressing a significant gap in therapeutic options.